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Abstract
As targets of adaptive immunity, influenza viruses are characterized by the fluidity with which they respond to the selective
pressure applied by neutralizing antibodies. This mutability of structural determinants of protective immunity is the
obstacle in developing universal influenza vaccines. Towards the development of such vaccines and other immune
therapies, our studies are designed to identify regions of influenza viruses that are conserved and that mediate virus
neutralization. We have specifically focused on viruses of the H3N2 subtype, which have persisted as a principal source of
influenza-related morbidity and mortality in humans since the pandemic of 1968. Three monoclonal antibodies have been
identified that are broadly-neutralizing against H3 influenza viruses spanning 40 years. The antibodies react with the
hemagglutinin glycoprotein and appear to bind in regions that are refractory to the structural variation required for viral
escape from neutralization. The antibodies demonstrate therapeutic efficacy in mice against H3N2 virus infection and have
potential for use in the treatment of human influenza disease. By mapping the binding region of one antibody, 12D1, we
have identified a continuous region of the hemagglutinin that may act as an immunogen to elicit broadly protective
immunity to H3 viruses. The anti-H3 monoclonal antibodies were identified after immunization of mice with the
hemagglutinin of four different viruses (A/Hong Kong/1/1968, A/Alabama/1/1981, A/Beijing/47/1992, A/Wyoming/3/2003).
This immunization schedule was designed to boost B cells specific for conserved regions of the hemagglutinin from distinct
antigenic clusters. Importantly, our antibodies are of naturally occurring specificity rather than selected from cloned
libraries, demonstrating that broad-spectrum humoral immunity to influenza viruses can be elicited in vivo.
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Introduction
Under non-pandemic conditions, the global mortality attributed
to influenza virus infection is considerable, with 200,000–500,000
associated deaths occurring each year [1]. In the setting of the
1918 influenza pandemic, the global mortality reached 50 million
people in one year, equivalent to twice the number of people killed
by HIV/AIDS since its emergence almost thirty years ago [2].
Notably, in 1918 and in the current swine-origin influenza virus
pandemic, the populations normally considered the fittest are
observed to be among the most vulnerable [3,4].
Four kinds of influenza viruses are circulating in the human
population at this time: influenza A viruses of the hemagglutinin
H3 and H1 subtypes (H1 viruses are further divided into those of
human and swine origin) and influenza B viruses. Influenza A
viruses are responsible for the bulk of seasonal disease, with H3
viruses dominating eight of the past twelve influenza seasons in the
United States [5]. In 1968, an H3 virus caused one of the three
major influenza pandemics of the twentieth century and H3
viruses have persisted since that time as a significant agent of
human disease. In addition to humans, H3 influenza viruses
commonly infect birds, swine, and horses. It is not known whether
H3 viruses will persist as human pathogens or how they may
evolve to become more or less virulent in humans.
Immunity to influenza viruses is currently achieved by
vaccination with strains representing those predicted to circulate
in the coming flu season. In a healthy person, the virus acts as a
robust immunogen, eliciting neutralizing serum antibody that
protects against influenza disease. Both the humoral and cell-
mediated arms of the adaptive system are involved in resolution of
active influenza infection, with neutralizing antibody titers
correlating with protection in vivo [6].
The hemagglutinin glycoprotein is the primary target of
antibodies that confer protective immunity to influenza viruses.
Antibodies to other influenza proteins likely act in: Fc-receptor
mediated uptake of virus particles, antibody-dependent cell
cytotoxicity, delay of replication kinetics and, in aggregate, they
may contribute to virus neutralization. On a monoclonal level,
however, only antibodies specific for the viral hemagglutinin have
been shown to block/neutralize infection [7].
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either of the two functions of the hemagglutinin molecule: virus
attachment or virus fusion with the host cell [8]. Antibodies that
prevent attachment bind antigenic sites surrounding the receptor
binding pocket in the membrane distal HA1 subunit of the
hemagglutinin and restrict the association with host cell receptors
(sialic acids) [9]. These antibodies drive the outgrowth of antigenic
variants, resulting in a continuum of changes in the hemagglutinin
structure known as ‘antigenic drift’. Relatively few examples of
fusion-inhibiting mAbs are available, but they are most commonly
described to interact with the membrane proximal HA2 portion of
the hemagglutinin in the region of the fusion peptide [10,11,12].
The sixteen subtypes of the influenza hemagglutinin are divided
broadly into two phylogenetic groups that correlate with two basic
structures taken by the stalk of the molecule [13]. In 1993, mAb
C179, an antibody with broad neutralizing activity against viruses
in Group 1 (of H1 and H2 subtypes) was described [14]. More
recently, several other monoclonal antibodies that neutralize a
broad array of Group 1 viruses (including representative H1 and
H5 viruses) were identified [11,12,15,16]. These antibodies have
consistently been shown to interact with the stalk of the
hemagglutinin and neutralize virus by preventing fusion with the
host cell. This report constitutes the first description of broadly
neutralizing antibodies against viruses in Group 2.
Results
Isolation of broadly-reactive anti-H3 mAbs
In order to enhance the production of cross-reactive antibody
specificities, we immunized mice by sequential administration with
DNA coding for the hemagglutinin from H3 viruses arising
approximately 10 years apart: A/Hong Kong/1/1968, A/
Alabama/1/1981, A/Beijing/47/1992. Finally, three days prior
to fusion, mice were boosted with the H3 virus A/Wyoming/3/
2003. By performing the fusion rapidly after virus boost we
ensured that only hemagglutinin-specific B cells were present in
the spleen at time of fusion. The hemagglutinins chosen were from
viruses that arose over several decades, thus representing multiple
H3 antigenic clusters [17]. Post-fusion, hybridoma supernatants
were screened for the ability to bind A/Hong Kong/1/1968 by
western blot or by ELISA and successive rounds of subcloning
were performed on positive supernatants until monoclonal
hybridoma populations were isolated.
The immunization schedule we utilized successfully elicited the
production of antibodies with broad reactivity against H3 viruses.
Approximately 120 clones were isolated that reacted with A/Hong
Kong/1/1968; of those, eight mAbs were cross-reactive against all
of the H3 hemagglutinins tested. Interestingly, the particular
immunization protocol also preferentially elicited the production
of antibodies specific for the HA2 subunit of the hemagglutinin. Of
the 8 mAbs identified, 5 mAbs react with HA2 and 1 mAb reacts
with HA1 by western blot. The remaining 2 mAbs bind
conformational epitopes present in the HA trimer as detected by
western blot of purified H3 virus proteins separated under non-
reducing gel conditions. All mAbs were reactive in a purified H3
virus ELISA. Three of the mAbs, 7A7, 12D1, 39A4, had the
highest activity by ELISA and were selected for thorough
characterization (Table 1, Figure 1).
Antibodies 7A7, 12D1 and 39A4 react by ELISA with purified
A/Alabama/1/1981 and purified A/Hong Kong/1/1968 viruses
Figure 1. MAbs react with H3 hemagglutinin by western blot.
(A) MAb 12D1 binds the A/Pan/2007/1999 hemagglutinin within the
HA2 subunit. mAbs 7A7 and 39A4 do not react with hemagglutinin
under reducing conditions. (B) MAbs 7A7, 12D1 and 39A4 react with
the A/HK/1/1968 hemagglutinin under non-reducing conditions. MAbs
7A7 (lane 1) and 39A4 (lane 3) bind HA trimer complexes. mAb 12D1
(lane 2) binds HA trimer complexes and HA0.
doi:10.1371/journal.ppat.1000796.g001
Author Summary
Influenza viruses remain a formidable public health threat.
Because of a dramatic increase in drug resistant strains of
influenza viruses and due to the semi-regular emergence
of pandemic virus strains, the development of novel
antibody-based therapies and influenza vaccine constructs
is of great interest. Recently, monoclonal antibodies with
broad neutralizing activity against an array of Group 1
influenza viruses (including H5 and H1 subtypes) were
identified; studies using these antibodies have expanded
our understanding of structural aspects of the viral
hemagglutinin, the molecule mediating protective immu-
nity to influenza viruses. We have identified the first
broadly neutralizing antibodies against viruses in Group
2—specifically, they are active against H3 influenza viruses
spanning 40 years. The antibodies react with the
hemagglutinin and appear to bind in regions that are
refractory to the structural variation required for viral
escape from neutralization. The antibodies demonstrate
therapeutic efficacy in mice against H3N2 virus infection
and have potential for use in the treatment of human
influenza disease. By mapping the binding region of one
antibody, 12D1, we have identified a continuous region of
the hemagglutinin that may act as an immunogen to elicit
an immune response conferring broad protection against
H3 viruses.
Table 1. Pattern of reactivity of anti-H3 mAbs.
Isotype ELISA WB HI
7A7 IgG2b + Trimer 2
12D1 IgG1 + HA2 2
39A4 IgG2a + Trimer 2
62F11 IgG2a + HA2 2
36A7 IgG2b + HA2 2
66A6 IgG1 + HA1 2
49E12 IgG2b + HA2 2
21D12 IgG1 + HA2 2
All mAbs have activity by ELISA and all mAbs react by western blot under
reducing conditions except mAbs 7A7 and 39A4 that react with the HA trimer
under non-reducing conditions. All mAbs are negative for hemagglutination
inhibition (HI) activity at 50ug/ml.
doi:10.1371/journal.ppat.1000796.t001
Cross-Protective mAbs against H3 Influenza Viruses
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Hong Kong/1/1968 virus [18]. MAbs 7A7, 12D1 and 39A4 show
broad reactivity by immunofluorescence against cells infected with
all H3 viruses spanning 40 drift years. MAbs 7A7 and 39A4 also
react by immunofluorescence with other influenza A viruses
chosen at random, including representative H1, H2 and equine
H3 viruses (Table 2).
Anti-H3 mAbs neutralize H3 viruses spanning 40 drift
years
The anti-H3 mAbs were first evaluated for their ability to
neutralize H3 influenza viruses by microneutralization assay.
Viruses used in this assay contain a gene segment coding for firefly
luciferase in place of the viral hemagglutinin; a hemagglutinin is
present on the viral envelope due to propagation of virus in cells
stably expressing a particular H3 hemagglutinin protein (see
methods). Luciferase viruses were generated that express the
hemagglutinin of A/HK/1968 or A/Panama/99 viruses. Neu-
tralization of viruses by anti-H3 mAbs was determined based on
luciferase activity after single-cycle replication; mAbs 7A7, 12D1
and 39A4 were determined to neutralize the hemagglutinin of
both A/HK/1968 and A/Pan/99 (Figure 3).
Next, we evaluated neutralization activity by plaque reduction
assay. The anti-H3 mAbs were able to prevent infection (not
simply reduce plaque size) of Madin Darby canine kidney cells by
H3 viruses arising over 40 drift years: A/HK/1968, A/BJ/1992,
A/Pan/99, A/Bris/07, A/NY/08 (Figure 4). We tested 7A7,
12D1 and 39A4 against representative H4 and H7 viruses (Group
2) as well as an H1 virus (Group 1) and found that they did not
neutralize the non-H3 subtype viruses (Figure 4).
Anti-H3 mAbs in the treatment of influenza in mice
The three mAbs were tested in vivo for use as passive transfer
therapies in disease caused by H3 virus infection. Mice were given
30mg/kg mAb intraperitoneally either 1 hour before, 24 hours
post or 48 hours post challenge with 10 mouse LD50 reassortant
H3 virus (the A/HK/68 reassortant virus contains the six non-
hemagglutinin, non-neuraminidase segments from the mouse-
adapted A/PR/8 virus). Mice were weighed daily and were
sacrificed if they reached 75% of their starting weight. Treatment
of mice with mAb 12D1 either prophylactically or therapeutically
was 100% protective. mAb 39A4 was evaluated for efficacy by
prophylactic treatment and was similarly 100% protective in vivo.
Mice treated prophylactically with mAb 7A7 were only 40%
protected against the A/HK/68 reassortant virus (Figure 5).
Next, the effect of prophylactic treatment with mAb 12D1 or
39A4 on lung damage caused by H3 viral pneumonia was assessed
by histologic evaluation of tissue taken 4 days post infection with
the A/HK/68 reassortant virus. Without treatment, lungs showed
degenerative changes with focal hemorrhaging, dense neutrophilic
infiltrates and diffuse alveolar damage with edema. Treatment
with either anti-H3 mAb significantly diminished pathologic
changes (Figure 6).
Having demonstrated protective activity in vivo against the A/
HK/68 reassortant virus we sought to evaluate cross-protection
mediated by mAbs 12D1 and 39A4 against a second H3 virus, A/
Georgia/1981. MAbs 12D1 and 39A4 were administered as
described above to BALB/c mice one hour prior to infection. Mice
were then infected intranasally with 2700 pfu A/Georgia/1981
Figure 2. Reactivity of anti-H3 mAbs by ELISA. (A) mAbs react with purified A/HK/1968 (H3) virus. (B) mAbs react with purified A/Alabama/1981
(H3) virus. mAb XY102 is specific for the hemagglutinin of A/HK/1968 virus.
doi:10.1371/journal.ppat.1000796.g002
Table 2. Reactivity of mAbs at 5ug/ml by
immunofluorescence against MDCK cells infected with a panel
of randomly chosen viruses.
Virus Subtype 7A7 12D1 39A4 10C4 XY102
HK/68 H3 ++ + 2 +
AL/81 H3 ++ + 22
BJ/92 H3 ++ + 22
WI/05 H3 ++ + 22
BR/07 H3 ++ + 22
NY/08 H3 ++ + 22
TX/91 H1 + 2 ++2
FM/47 H1 + 2 + 22
AA/60 H2 + 2 + 22
Equine/KY/02 H3 + 2 + 22
MAb XY102 was generated by immunization with A/HK/1968 (H3) virus and
mAb 10C4 was generated by immunization with A/TX/1991 (H1) virus.
doi:10.1371/journal.ppat.1000796.t002
Cross-Protective mAbs against H3 Influenza Viruses
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H3 mAbs were found to reduce lung titers by 97.75% (12D1) or
99.03% (39A4) (Figure 7).
Anti-H3 mAbs act by inhibiting viral fusion
In order to determine the mechanism of virus neutralization by
our anti-H3 mAbs, we first looked at the ability of the mAbs to
inhibit virus hemagglutination of chicken red blood cells. We
found that none of the three mAbs had hemagglutination
inhibition activity, suggesting that the mAbs did not act by
obstructing the binding of virus to the host-cell.
Next, we tested the effect of the anti-H3 mabs on virus fusion.
MAbs 7A7, 12D1 and 39A4 were determined to inhibit the low-
pH fusion of A/HK/1968 virus with chicken red blood cells by at
least 80% at 10ug/ml (Figure 8).
Binding epitope of mab 12D1
Finally, we aimed to identify the region of the H3 hemagglutinin
that might elicit antibodies with fine specificities mirroring those of
12D1 or 39A4. Sixteen passages of A/HK/1968 virus in the
presence of the anti-H3 mAbs 12D1 or 39A4 did not yield escape
variants that might have assisted in identification of the binding
epitopes. Also, the hemagglutinin of six plaques present after
incubation of A/HK/1968 virus with 50ug/ml mAb 12D1 or
39A4 in a plaque assay was sequenced and we were surprised to
find no changes from the wild-type hemagglutinin.
Because mAb 12D1 mediates protection against influenza
disease in vivo and reacts with a continuous epitope of the viral
hemagglutinin (no trimeric structure required), as evidenced by
reactivity with the denatured hemagglutinin monomer by western
blot (Figure 1), we focused on identification of the 12D1 binding
epitope. Hemagglutinin truncation mutants consisting of hemag-
glutinin segments of varying length fused to GFP were generated.
GFP expression was utilized to assess expression of the constructs
in transfected 293T cells. By analysis of the truncation mutants, it
was determined that the 12D1 paratope makes dominant
interactions with the HA2 subunit in the region of amino acids
30–106. Diminished 12D1 binding without diminished GFP
expression in the 76–184 and 91–184 truncations along with loss
of binding with the 106–184 truncation suggested that 12D1
binding is dependent on contacts with amino acids in the HA2
76–106 region (Figure 9). These 30 amino acids fall within the
membrane distal half of the long alpha-helix of HA2 (Figure 10).
Figure 3. Anti-H3 mabs in microneutralization assay. Neutrali-
zation of virus expressing the HA from either (A) A/Hong Kong/1/1968
virus or (B) A/Panama/2007/1999 virus. mAb XY102 is specific for A/HK/
1968 virus. Purified mouse IgG was used for the negative control.
doi:10.1371/journal.ppat.1000796.g003
Figure 4. Activity of anti-H3 mabs in plaque reduction assay on
MDCK cells. mAb 7A7 (A), 12D1 (B) and 39A4 (C) neutralize all H3
viruses tested by plaque reduction assay but not representative H1, H4
or H7 viruses. Purified mouse IgG was used for the negative control. The
plaque reduction assays were performed multiple times and with each
new antibody preparation. Data shown are from a single representative
experiment.
doi:10.1371/journal.ppat.1000796.g004
Cross-Protective mAbs against H3 Influenza Viruses
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acids outside of this region (in HA1 or HA2) that are not required
for binding by western blot.
Discussion
For this study, we developed an immunization schedule that
elicited broadly-neutralizing antibodies against H3 influenza
viruses in vivo. The finding that such antibody specificities can be
elicited by vaccination of mice suggests that with the proper
immunogen(s) and vaccination protocol, such a response might
also be elicited in humans. Several recent studies describe
antibodies isolated from human phage display libraries that have
cross-neutralizing activity against Group 1 influenza viruses
[11,12,15,16]. Mabs isolated from human display libraries have
proved extremely useful in the characterization of structural
epitopes that mediate heterosubtypic neutralization. Caveats to
this methodology exist, however, since the diversity of combina-
torial display libraries is typically orders of magnitude greater than
the diversity of the true human variable region repertoire [19].
Additionally, phage display libraries are generated by random
combination of immunoglobulin VH and VL genes and are
therefore not restricted, as the in vivo repertoire is, by mechanisms
regulating the production of auto-reactive specificities.
Until now, broadly neutralizing antibodies reactive with H3
viruses have not been described. Interestingly, mAbs 7A7 and
39A4 react by immunofluorescence with the hemagglutinin of
multiple subtypes, though neutralizing activity appears to be
limited to H3 viruses. Binding by these mAbs to other subtypes
may be of relatively low avidity such that they no longer mediate
neutralization, or, they may simply bind an epitope of non-H3
hemagglutinins that does not mediate neutralization. The
identification of anti-H3 mAbs 12D1 and 39A4 complements
recent works describing antibodies F10 and CR6261 that
neutralize an array of Group 1 viruses [11,12,16]. One might
envision a passive transfer therapy consisting of multiple broadly
neutralizing mAbs for general use against pandemic and seasonal
influenza virus strains. With the increasing resistance of influenza
virus isolates to available anti-viral drugs, such an antibody
cocktail could be of great value in severe disease.
Mouse monoclonal antibodies such as the anti-H3 mabs
described herein are commonly used in the development of
therapeutic antibodies for use in humans. Once characterized,
rodent antibodies are readily humanized by methods typically
involving grafting of non-human complimentary determining
regions into appropriate human frameworks followed by cloning
of variable region segments into complete human immunoglobulin
constructs [20].
Figure 5. Anti-H3 mAbs protect against H3 virus in vivo. Mice
were given 30mg/kg mAb 7A7, 12D1, 39A4 or isotype control by
intraperitoneal injection 1 hour prior, 24 hours post (12D1 only) or
48 hours post (12D1 only) challenge with H3N2 reassortant virus (HK68/
PR8). N=5 per group.
doi:10.1371/journal.ppat.1000796.g005
Figure 6. Treatment with anti-H3 mAbs diminishes lung damage associated with viral pneumonia caused by HK68/PR8 reassortant
virus. (A,B) Untreated (C,D) mice treated with mAb 39A4 (E,F) mice treated with mAb 12D1. 406magnification.
doi:10.1371/journal.ppat.1000796.g006
Cross-Protective mAbs against H3 Influenza Viruses
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passages of virus in the presence of anti-H3 mabs 12D1 and 39A4
is intriguing. Sui et al. reported that they were similarly unable to
isolate escape mutants using their fusion-inhibiting mAb F10 [11].
MAb F10 makes multiple interactions with the hydrophobic
pocket of the hemagglutinin including with the fusion peptide itself
and prevents the low-pH triggered conformation change required
for fusion. Considering the rigid structural and electrostatic
requirements involved in membrane fusion, the hemagglutinin
might not readily accommodate mutations at the F10 binding
epitope. Anti-H3 mAb 39A4 binds a conformational epitope of the
hemagglutinin trimer; the region of binding may bridge two
monomers, therefore interacting with two different portions/faces
of each monomer. A mutation at one region of contact (that does
not affect trimer formation) may not be sufficient to ablate 39A4
binding. Anti-H3 mAb 12D1 likely binds within the long alpha-
helix of HA2. This region may not accommodate changes that
would affect 12D1 binding due to required secondary helix
structure and specific van der Waals interactions that stabilize the
hemagglutinin trimer [21]. Generally, mutations in the stalk of
the hemagglutinin are more likely to affect the architecture of
the entire molecule than are mutations in the classical antigenic
sites [9].
The development of HA2-based vaccine constructs is of
significant interest given recent reports of anti-HA2 mAbs with
broad neutralizing activity against influenza viruses. Original
studies of immunogens consisting of virus particles lacking the
HA1 subunit demonstrated that design of an effective construct,
however, will likely not be straightforward [22]. This is in large
part due to the difficulty involved in maintaining the native
configuration of the hemagglutinin stalk, which has complex
tertiary structure and incorporates a portion of HA1 in addition to
the HA2 subunit. Recent reports of mAbs with broad neutralizing
activity against influenza viruses that are not active by western blot
and that make contacts with amino acids in both HA1 and HA2
underscore the importance of maintaining non-contiguous epi-
topes in HA2 vaccine contructs [12,16,20].
In contrast to these mAbs, anti-H3 mAb 12D1 does not rely on
a structural/non-contiguous epitope of the hemagglutinin stalk for
binding. The observation that 12D1 makes dominant contacts
within a continuous segment of the HA2 subunit suggests the
design of an immunogen, perhaps consisting of that HA2 segment
coupled to a carrier protein, that would direct an immune
response to the region. The identified region, HA2 76–106, is
100% conserved between the H3 viruses used in this study and all
other H3 viruses that we have examined. In contrast, the H1
viruses A/New Caledonia/20/99 and A/PR/8/34 share only
56.7% identity with the equivalent region in the H3 hemagglu-
tinin. A vaccine construct incorporating this region, therefore,
would likely not provide protection against H1 influenza viruses.
This study and other structural studies [11,12,14] of the influenza
hemagglutinin provide groundwork for the design of novel vaccine
constructs aimed at providing broad-spectrum immunity to
influenza viruses.
Materials and Methods
Animals
6 week old female BALB/c mice from Jackson Laboratory were
used for all experiments. All animal procedures performed in this
study are in accordance with Institutional Animal Care and Use
Committee (IACUC) guidelines, and have been approved by the
IACUC of Mount Sinai School of Medicine.
Viruses and cells
Madin Darby canine kidney cells from ATCC were used for all
cell based assays. Cells were maintained in minimum essential
medium supplemented with 10% fetal bovine serum, and 100
units/ml of penicillin-100 mg/ml of streptomycin. All viruses were
propagated in eggs. Viruses used in various studies: A/Hong
Kong/1/1968 (HK/68) (H3), A/Alabama/1/1981 (AL/81) (H3),
A/Georgia/1981 (H3), A/Beijing/47/1992 (BJ/92) (H3), A/
Wyoming/3/2003 (H3), A/Wisconsin/67/2005 (WI/05) (H3),
A/Brisbane/10/2007 (BR/07) (H3), A/New York/2008 (NY08)
(H3), A/Texas/36/1991 (TX/91) (H1), A/New Caledonia/20/99
(N.Cal/99) (H1), A/Duck/England/1962 (Dk/62) (H4), A/
Turkey/England/1963 (Tky/63) (H7), A/Equine/Kentucky/
2002 (e/KY/02) (H3), A/Ann Arbor/6/1960 (AA/60) (H2), A/
Fort Monmouth/1/1947 (FM/47) (H1). Purified virus was
prepared by high speed centrifugation (43,000 rpm, 1 hour) of
allantoic fluid through a 20% sucrose cushion.
Figure 8. Red blood cell fusion assay. Anti-H3 mabs inhibit low-pH
induced fusion of HK/68 hemagglutinin with chicken red blood cells. All
mAbs are negative for hemagglutinin-inhibition activity. MAb 1A7 is
specific for influenza virus NS1 protein.
doi:10.1371/journal.ppat.1000796.g008
Figure 7. Anti-H3 mAbs protect against replication of H3 virus
in lungs. Mice were given 30mg/kg mAb 12D1, 39A4 or isotype control
by intraperitoneal injection 1 hour prior to infection with A/Georgia/
1981 virus. Data represent lung titers from groups of 5 mice, 2 days post
infection.
doi:10.1371/journal.ppat.1000796.g007
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Hybridoma supernatants were used for screening of mAbs for
reactivity by enzyme-linked immunosorbent assay (ELISA) and by
western blot. For other assays, purified monoclonal antibody or
ascites preparations treated with receptor-destroying enzyme [23]
were used. RDE –treated ascites was used for measurement of
binding by ELISA, microneutralization, plaque reducion and
fusion assays. Antibodies were purified by methods previously
described [24]. Because of differences in isotypes, Protein A-
agarose (Roche) was used for purification of mAbs 7A7 and 39A4
while protein G-agarose (Roche) was used for purification of mAb
12D1.
Immunization of mice and hybridoma production
6-week old BALB/c mice were immunized with DNA
constructs coding for the open-reading frame of influenza virus
hemagglutinin in the pCAGGS plasmid [25]. Individual immu-
nizations were given intramuscularly, 3-weeks apart and consisted
of 100ug DNA in 100ul PBS. Hemagglutinins utilized in the
immunization schedule were cloned from the following parental
viruses - primary immunization: A/Hong Kong/1/1968, second-
ary immunization: A/Alabama/1/1981, tertiary immunization:
A/Beijing/47/1992 HA. Three days prior to fusion, mice were
boosted with 50ug purified A/Wyoming/3/2003 virus. B cell
hybridomas were produced by methods previously described
[26,27].
Screening of hybridoma supernatants
Hybridoma supernatants were screened by blot and by ELISA
for reactivity with A/Hong Kong/1/1968 virus. For the ELISA,
direct binding to wells coated with 5ug/ml purified virus, 50ul per
well was assessed. For the blot assay, 10ug purified virus was
adsorbed onto nitrocellulose strips and individual strips were
incubated with hybridoma supernatants. For the ELISA and blot
assays, binding of antibody to virus was detected using goat anti-
mouse c-chain horse radish peroxidase secondary antibody
(SouthernBiotech, Birmingham, Al). All wells that had activity in
either assay against A/Hong Kong/1/1968 virus were subcloned
repeatedly to ensure the monoclonality of the hybridoma
populations.
Figure 9. MAb 12D1 reacts by western blot with hemagglutinin truncation mutants. 12D1 makes dominant contacts with the HA2 subunit
in the region of amino acids 30 to 106 (H3 numbering[21]). Diminished 12D1 binding without diminished GFP expression in the HA2 76–184 and HA2
91–184 truncations along with loss of binding with the HA2 106–184 truncation suggests that the binding epitope lies in the region from amino acids
HA2 76–106. These 30 amino acids fall within the membrane distal half of the long alpha-helix of HA2.
doi:10.1371/journal.ppat.1000796.g009
Figure 10. Region of dominant contacts between anti-H3 mab
12D1 and HA2. mAb 12D1 makes contact in the HA2 region (blue) of
the viral hemagglutinin. Evaluation of binding to hemaggluinin
truncation mutants demonstrates binding within the region of amino
acids 76–106 of HA2 (light blue).
doi:10.1371/journal.ppat.1000796.g010
Cross-Protective mAbs against H3 Influenza Viruses
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Blots were produced by methods previously described [28].
Samples were boiled for 5 minutes at 100uC in loading buffer
containing SDS and 0.6M DTT. SDS migration buffer was used
for electrophoresis. For non-reducing gel conditions samples were
prepared in loading buffer with SDS but without reducing agent
and were not boiled.
Immunofluorescence test
MDCK cells were infected with virus at a multiplicity of
infection of 1 and incubated for 6 hours at 37uC. Infected and
uninfected cells were incubated with 1ug/ml mAb for 1 hour at
room temperature. Goat anti-mouse fluorescein conjugate (South-
ernBiotech) was used for detection of mAb binding.
Microneutralization assay
Two stable cell lines were generated that expressed the HA of
A/Hong Kong/1/1968 virus or A/Panama/2007/1999 virus.
Pseudotyped viruses expressing the HA of either cell line were
generated by infection of cells with a virus that carries seven
segments from A/WSN/33 virus (all except the HA segment) and
one segment encoding Renilla luciferase. Pseudotyped viruses
expressing the HA of A/Hong Kong/1/1968 virus or A/
Panama/2007/1999 virus were used as the neutralization target.
Viruses were incubated with mAb at room temperature for
30 minutes, rocking. Purified polyclonal mouse IgG (Invitrogen)
was used for the negative control. The mixture containing virus
and mAb was then transferred to wells of a 96-well plate seeded
to confluency with MDCK cells and incubated for 12 hours
at 37uC. Individual determinants were performed in triplicate.
After incubation, luciferase activity in cell-lysates was measured
as a read-out of virus infection (Renilla luciferase assay system,
Promega).
Plaque reduction assay
Antibody and virus (,50 pfu/well) were co-incubated at room
temperature for 30 minutes, rocking. 6 well plates seeded with
MDCK cells were washed once with PBS and 200ul of virus and
mAb was added to each well then incubated for 20 minutes, 37uC.
Virus with mAb was aspirated from cells and an agar overlay
containing antibody was added to each well. Plates were incubated
for 3 days, 37uC and plaques were counted by crystal violet
staining. Purified mouse IgG (Invitrogen) was used for the negative
control.
Passive transfer experiments
Before infection, mice were anesthetized by intraperitoneal
administration of a ketamine (75 mg/kg of body weight)/xylazine
(15 mg/kg of body weight) mixture. 6 week old BALB/c mice
were given 30mg/kg mAb intraperitoneally either one hour
before, 24 hours after or 48 hours after challenge with 10 LD50 A/
Hong Kong/1/1968, A/PR/8/34 reassortant virus or 2700 pfu
A/Georgia/1981 virus (lung titer experiment). Purified mouse IgG
(Invitrogen) was used for the negative control. Virus was
suspended in PBS and administered intranasally in 50ul (25ul
per nostril). Mice were weighed daily and sacrificed if they fell to
75% of starting weight. For the lung titer experiment, mouse lungs
were harvested 4 days post infection with A/Georgia/1981 and
virus titers in lung homogenates were determined by plaque assay.
For histologic evaluation of lung damage, lungs were harvested 4
days post infection with A/Hong Kong/1/1968 - A/PR/8/34
reassortant virus. Tissues were imbedded in paraffin and sections
were stained with hematoxylin and eosin.
Hemagglutinin inhibition assay and fusion assay
MAbs were tested in a standard hemagglutination inhibition
assay [29] using chicken red blood cells and A/Hong Kong/1/
1968 virus. For the red blood cell fusion assay, virus was incubated
with chicken red blood cells (2% final red cell concentration) on ice
for 10 minutes. Dilutions of antibody were added and samples
were incubated on ice for 30 minutes. Sodium citrate buffer,
pH 4.6 was then added to bring the final pH to 5.0 and samples
were incubated for 30 minutes at room temperature. Samples
were centrifuged for 3 minutes at 3000rpm to pellet red blood cells
and supernatants were then transferred to an ELISA plate for
determination of NADPH content by optical density measurement
(340nm). NADPH was present in the supernatant as a function of
fusion-induced red blood cell lysis.
Hemagglutinin truncation mutants
DNA constructs were generated in the pCAGGS plasmid that
coded for truncations of the A/HK/1/68 virus hemaggluinin
fused to green fluorescent protein. All constructs were sequenced
and confirmed. 293T cells were then transfected using Lipofecta-
mine 2000 (Invitrogen, Inc.) with the various pCAGGS encoding
the HA-GFP fusion gene. Cell lysates were resolved in a 4–20%
Tris-HCl SDS-PAGE gel (Bio-Rad Laboratories) and proteins
were blotted onto a Protran nitrocellulose membrane (Whatman).
GFP and truncated HA fragments were detected using rabbit anti-
GFP (Santa Cruz Biotechnology, Inc.) and anti-H3 mAb 12D1
respectively. Secondary antibodies were anti-rabbit IgG HRP
(Dako) and anti-mouse Ig HRP(GE Healthcare).
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